WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Prostate Cancer Efficacy Endpoints_v3, Patient Reported Outcomes defined as Fatigue, Patient Reported Outcomes defined as Pain, Existing lesion identified by Anatomical region, Time-To-Event end points include Time to First Skeletal-related Event, Therapeutic Efficacy Endpoint is intersection of Therapeutic Intervention, Time to PSA Progression measured with PSA, New lesion identified by Organ specific lesion ID, New Lesion has Organ specific lesion ID, Sum of longest diameters (SLD) have response options -Complete Response (CR) -Partial Response (PR) -Not all evaluated -Stable disease (SD) -Progressive disease (PD) -Any, LD (axial plane) for target lesion measured in mm, - CR - PR differentiated into Unconfirmed Response, Time to opiate use derived from Pain Assessment Tool, Overall Survival (OS) derived from Circulating Tumor Cells (CTC), Therapeutic Efficacy Endpoint is intersection of Observation or Assessment, Time-To-Event end points include Time to Clinical Progression, Time to Pain Progression derived from Pain Assessment Tool, Anatomical region instantiated by -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, Bone Disease derived from Bone Scintigraphy, Sum of longest diameters (SLD) has component LD (axial plane) for target lesion, Overall Survival (OS) measured by Date of Randomization